About Samsung Bioepis
Samsung Bioepis is a company based in Incheon (South Korea) founded in 2012 was acquired by Samsung BioLogics in January 2022. Samsung Bioepis operates in a competitive market with competitors including Merck, Roivant Sciences, Gilead, Lilly and Aclaris Therapeutics, among others.
- Headquarter Incheon, South Korea
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Samsung Bioepis Co., Ltd
-
Annual Revenue
$660.03 M (USD)2as on Dec 31, 2020
-
Net Profit
$117.14 M (USD)-48as on Dec 31, 2020
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Samsung BioLogics
(Jan 27, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Samsung Bioepis
Detailed funding history for Samsung Bioepis
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in Samsung Bioepis
Samsung Bioepis has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Samsung BioLogics.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Contract development and manufacturing for biologics are provided.
|
Locked | Locked | Locked |
Investor details for Samsung Bioepis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Samsung Bioepis
Investment portfolio details for Samsung Bioepis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Samsung Bioepis
Detailed financials for Samsung Bioepis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Samsung Bioepis Comparisons
Peer comparison for Samsung Bioepis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Samsung Bioepis
Samsung Bioepis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Merck, Roivant Sciences, Gilead, Lilly and Aclaris Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Pharmaceutical products are manufactured and marketed worldwide.
|
|
| Locked | Locked | Locked |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others
|
|
| Locked | Locked | Locked |
Traditional pharmaceutical medicines are developed for multiple health fields.
|
|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Developer of drugs for the treatment of multiple disorders
|
Detailed competitors of Samsung Bioepis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Samsung Bioepis
Complete news archive for Samsung Bioepis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Samsung Bioepis
Samsung Bioepis was founded in 2012.
Samsung Bioepis is headquartered in Incheon, South Korea.
Annual revenue of Samsung Bioepis is $660.03M as on Dec 31, 2020.
Developer of biosimilar drugs for the treatment of multiple diseases. It is a Joint venture formed by the collaboration of Samsung Biologics and Biogen to develop biosimilars of advanced biologics to treat conditions such as rheumatoid arthritis, psoriasis, and Crohns disease. Ontruzant is Samsung Bioepis first cancer biosimilar approved by the FDA. It provides biosimilar of Etanercept, Infliximab, Adalimumab, Trastuzumab, Bevacizumab, etc.
Samsung Bioepis's top competitors include Merck, Roivant Sciences and AbbVie.
Samsung Bioepis has 1 investor. Key investors include Samsung BioLogics.